CN115066420B - 光学拆分的Trolox中间体和其制造方法 - Google Patents

光学拆分的Trolox中间体和其制造方法 Download PDF

Info

Publication number
CN115066420B
CN115066420B CN202180015723.7A CN202180015723A CN115066420B CN 115066420 B CN115066420 B CN 115066420B CN 202180015723 A CN202180015723 A CN 202180015723A CN 115066420 B CN115066420 B CN 115066420B
Authority
CN
China
Prior art keywords
trolox
formula
amide
compound
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180015723.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN115066420A (zh
Inventor
黑田贵一
泽村洁人
露峰信二郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Publication of CN115066420A publication Critical patent/CN115066420A/zh
Application granted granted Critical
Publication of CN115066420B publication Critical patent/CN115066420B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180015723.7A 2020-02-21 2021-02-19 光学拆分的Trolox中间体和其制造方法 Active CN115066420B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020028614 2020-02-21
JP2020-028614 2020-02-21
PCT/JP2021/006465 WO2021167095A1 (ja) 2020-02-21 2021-02-19 光学分割されたトロロックス中間体およびその製造方法

Publications (2)

Publication Number Publication Date
CN115066420A CN115066420A (zh) 2022-09-16
CN115066420B true CN115066420B (zh) 2024-12-10

Family

ID=77390820

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180015723.7A Active CN115066420B (zh) 2020-02-21 2021-02-19 光学拆分的Trolox中间体和其制造方法

Country Status (8)

Country Link
US (1) US12509434B2 (https=)
EP (1) EP4108658A4 (https=)
JP (2) JP7840259B2 (https=)
KR (1) KR20220143897A (https=)
CN (1) CN115066420B (https=)
BR (1) BR112022016508A2 (https=)
IL (1) IL295785A (https=)
WO (1) WO2021167095A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20250133A (es) 2022-09-12 2025-06-26 Ptc Therapeutics Inc Granulos para suspension
AU2023352262A1 (en) 2022-09-30 2025-04-24 Ptc Therapeutics, Inc. Oxidative cleavage method of trolox amide
WO2025117870A1 (en) 2023-12-01 2025-06-05 Ptc Therapeutics, Inc. Method of electrolytic oxidative cleavage of trolox amide
WO2025193975A1 (en) 2024-03-13 2025-09-18 Ptc Therapeutics, Inc. Formulations for stabilizing dissolution of medicaments

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1456827A (en) * 1972-12-22 1976-11-24 Hoffmann La Roche Chromane derivatives

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947473A (en) 1972-12-22 1976-03-30 Hoffman-La Roche Inc. Antioxidant chroman compounds
US4003919A (en) 1973-11-19 1977-01-18 Hoffmann-La Roche Inc. Antioxidant chroman compounds
US4026907A (en) 1973-11-19 1977-05-31 Hoffmann-La Roche Inc. Antioxidant chroman compounds
WO2002012221A1 (en) * 2000-08-03 2002-02-14 Kuraray Co., Ltd. Method for optical resolution of (±)-6-hydroxy-2,5,7,8-tetramethylcoumarone-2-carboxylic acid
JP2002167381A (ja) * 2000-08-03 2002-06-11 Kuraray Co Ltd （±）−６−ヒドロキシ−２，５，７，８−テトラメチルクロマン−２−カルボン酸の光学分割法
EA038941B1 (ru) 2007-11-06 2021-11-12 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
JP5598330B2 (ja) * 2008-10-29 2014-10-01 三菱瓦斯化学株式会社 光学活性有機カルボン酸の製造方法
KR20110086723A (ko) 2008-11-07 2011-07-29 시플라 리미티드 조피클론을 광학분할하는 방법
JP5641802B2 (ja) * 2010-07-26 2014-12-17 株式会社トクヤマ （ｓ）−４−〔（４−クロロフェニル）（２−ピリジル）メトキシ〕ピペリジンのジアステレオマー塩の製造方法
JPWO2013011999A1 (ja) * 2011-07-20 2015-02-23 株式会社カネカ 光学活性２−メチルプロリン誘導体の製造法
CN105164105B (zh) 2013-04-10 2018-01-30 第一三共株式会社 吡咯衍生物的结晶及其制备方法
DK3233786T3 (da) * 2014-12-16 2022-05-09 Ptc Therapeutics Inc Polymorfe og amorfe former af (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6- dioxocyclohexa-1,4-dienyl)butanamid
EP3233819A1 (en) * 2014-12-16 2017-10-25 Bioelectron Technology Corporation Methods for chiral resolution of trolox
JP2020028614A (ja) 2018-08-24 2020-02-27 株式会社三共 遊技機

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1456827A (en) * 1972-12-22 1976-11-24 Hoffmann La Roche Chromane derivatives

Also Published As

Publication number Publication date
IL295785A (en) 2022-10-01
US12509434B2 (en) 2025-12-30
JPWO2021167095A1 (https=) 2021-08-26
JP2026041900A (ja) 2026-03-10
EP4108658A4 (en) 2024-05-22
JP7840259B2 (ja) 2026-04-03
WO2021167095A1 (ja) 2021-08-26
CN115066420A (zh) 2022-09-16
EP4108658A1 (en) 2022-12-28
KR20220143897A (ko) 2022-10-25
US20230029044A1 (en) 2023-01-26
BR112022016508A2 (pt) 2022-10-11

Similar Documents

Publication Publication Date Title
CN115066420B (zh) 光学拆分的Trolox中间体和其制造方法
US8501753B2 (en) Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3, 5-dihydro-pyrrolo [3, 2-D] pyrimidin-4-one
US20090221595A1 (en) Crystalline form of sitagliptin
US11739057B2 (en) Polymorphic forms of Belinostat and processes for preparation thereof
WO2012077138A1 (en) Methods of crystallizing (r) -1- (3 -hydroxypropyl) -5- [2- [2- [2- ( 2, 2, 2 - trifluoroethoxy) phenoxy] ethylamino] propyl] indoline-7 -carboxamide
US10577340B1 (en) Beraprost-314d crystals and methods for preparation thereof
KR20100022081A (ko) 결정성 로티고틴 염기 및 이의 제조 방법
JP5336509B2 (ja) （ｒ）−３−フルオロフェニル−３，４，５−トリフルオロベンジルカルバミン酸１−アザビシクロ［２．２．２］オクト−３−イルエステルの安定な結晶性塩
JP2023521985A (ja) Ｓ－ピンドロールの有機酸付加塩
CN111995571A (zh) 一种瑞戈非尼与马来酸的共晶及其制备方法
CN109689620B (zh) 拆分巴氯芬盐的方法
TW202128604A (zh) 用於製備超純曲前列環素之高效結晶方法及由其製得之晶體
HK40079636A (en) Optically resolved trolox intermediate and method for producing same
JP4547245B2 (ja) ペリンドプリルエルブミンのｉ型結晶、及びその製造方法
JP5200245B2 (ja) Ｄｌ−バリンラセミ化合物の光学分割方法。
US10253011B1 (en) Lubiprostone crystals and methods for preparing the same
HK40104833A (en) Organic acid addition salts of s-pindolol
BR122025015739A2 (pt) Método de fabricação de um sal sólido, compostos, solvatos e ingredientes farmaceuticamente aceitáveis
CA3246483A1 (en) Crystal form of a fused ring derivative, a prepartion method therefor and use thereof
HK1112680A (en) Method of preparing tamibarotene crystal form ii
JP2016512257A (ja) 置換チアゾリル酢酸トリエチルアミン塩の結晶形態
WO2013114379A1 (en) Novel polymorphs of n-[2-amino-4-(4-fluorobenzylamino)-phenyl] carbamic acid ethyl ester and processes thereof
WO2021132297A1 (ja) カルバ環状ホスファチジン酸化合物
WO2021134921A1 (zh) 一种啶嘧磺隆晶型及其制备方法
US20090030207A1 (en) Polymorphs of Dolasetron base and process for preparation thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20241111

Address after: new jersey

Applicant after: PTC THERAPEUTICS, Inc.

Country or region after: U.S.A.

Address before: Osaka City, Osaka of Japan

Applicant before: SUMITOMO PHARMACEUTICALS CO.,LTD.

Country or region before: Japan

Applicant before: PTC THERAPEUTICS, Inc.

Country or region before: U.S.A.

GR01 Patent grant
GR01 Patent grant